Biomarker & Intervention Discovery

Atopic Dermatitis (Eczema)

This page lists 11 druggable gene targets, 52 approved or trial-tested drug candidates and 15 recent clinical trials for Atopic Dermatitis (Eczema), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Spontaneous remission60-70% of childhood-onset AD achieves spontaneous remission by adolescence; adult-onset AD is more persistent…
Best-intervention remissionDupilumab (anti-IL-4Rα): 51% IGA 0/1 (clear/almost clear) at 16 weeks in SOLO trials; tralokinumab (anti-IL-13): 38%…
Gap sizeLarge — most patients managed with topical steroids for decades without biologic assessment; biologics available since…
Primary barrieraccess/practice
Full remission profile →
Research Tracker Chronic Disease Interventions Atopic Dermatitis (Eczema)

Remission & chronicity

Spontaneous remission
60-70% of childhood-onset AD achieves spontaneous remission by adolescence; adult-onset AD is more persistent; moderate-severe adult AD: <15% spontaneous clearance at 5 years
Best-intervention remission
Dupilumab (anti-IL-4Rα): 51% IGA 0/1 (clear/almost clear) at 16 weeks in SOLO trials; tralokinumab (anti-IL-13): 38% clear/almost clear; baricitinib (JAK1/2i): 16% EASI-100 (complete clearance) at 16 weeks; upadacitinib (JAK1i): 28-40% EASI-100; near-complete clearance now achievable for most patients
Gap size
Large — most patients managed with topical steroids for decades without biologic assessment; biologics available since 2017 but reach only a fraction of eligible patients
Primary barrier
access/practice
Dupilumab approved 2017 but still not first-line in most health systems due to cost ($36,000/year); step therapy requirements force patients through years of topical steroids and immunosuppressants first; racial disparities in specialist access and biologic prescribing

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

AHR 254FLG 322IL13 10IL22 2IL31RA 1IL4 5IL4R 9JAK1 233OSMR 1PDE4D 204TSLP 51

AHR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
QUINALPHOS ? unclear Mechanistic DGIdb
BENZO(K)FLUORANTHENE ? unclear Mechanistic DGIdb
MICHLER'S KETONE ? unclear Mechanistic DGIdb
BENZO[B]FLUORANTHENE ? unclear Mechanistic DGIdb
PHENAZOPYRIDINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
ROMIPLOSTIM ? unclear Mechanistic DGIdb
CHRYSENE ? unclear Mechanistic DGIdb
TCDD ↑ activates Mechanistic DGIdb
COLFORSIN ? unclear Mechanistic DGIdb
CAFFEINE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL538965 ? unclear Mechanistic DGIdb
BENZO[DEF]CHRYSENE ? unclear Mechanistic 5.0 nM (EC50) DGIdb
QUESTIOMYCIN B ? unclear Mechanistic DGIdb
PENTACHLOROPHENOL ? unclear Mechanistic DGIdb
BETA-NAPHTHOFLAVONE ? unclear Mechanistic 1400.0 nM (EC50) DGIdb
SALICYLANILIDE ? unclear Mechanistic DGIdb
NAPHTHOQUINONE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL77675 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL70582 ? unclear Mechanistic DGIdb
CHRYSIN ? unclear Mechanistic DGIdb
RIMSULFURON ? unclear Mechanistic DGIdb
DIMETHYL YELLOW ? unclear Mechanistic DGIdb
METHYLCELLULOSE ? unclear Mechanistic DGIdb
TAPINAROF ↑ activates Mechanistic DGIdb
LEVOTHYROXINE ? unclear Mechanistic DGIdb
DIFLUBENZURON ? unclear Mechanistic DGIdb
1-NAPHTHYLISOTHIOCYANATE ? unclear Mechanistic DGIdb
NICLOSAMIDE ? unclear Mechanistic DGIdb
FLAVONE ? unclear Mechanistic DGIdb
DESMEDIPHAM ? unclear Mechanistic DGIdb
DESMETHOXYYANGONIN ? unclear Mechanistic DGIdb
PYRAFLUFEN-ETHYL ? unclear Mechanistic DGIdb
CYPRODINIL ? unclear Mechanistic DGIdb
EMODIN ? unclear Mechanistic DGIdb
NITAZOXANIDE ? unclear Mechanistic DGIdb
EZUTROMID ↓ inhibits Mechanistic DGIdb
CLIOQUINOL ? unclear Mechanistic DGIdb
2-CHLORO-5-NITRO-N-PHENYLBENZAMIDE ? unclear Mechanistic DGIdb
PIPERINE ? unclear Mechanistic DGIdb
METHABENZTHIAZURON ? unclear Mechanistic DGIdb

Showing top 40 of 254 agents ranked by evidence tier.

FLG

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DERAZANTINIB ↓ inhibits Mechanistic DGIdb
ENMD-981693 ↓ inhibits Mechanistic DGIdb
SUNITINIB ↓ inhibits Mechanistic DGIdb
ENTRECTINIB ? unclear Mechanistic DGIdb
FEXAGRATINIB ↓ inhibits Mechanistic DGIdb
PD173074 ? unclear Mechanistic DGIdb
AVUTOMETINIB ? unclear Mechanistic DGIdb
LUCITANIB ↓ inhibits Mechanistic DGIdb
ALSTERPAULLONE ? unclear Mechanistic DGIdb
DOVITINIB ↓ inhibits Mechanistic DGIdb
NINTEDANIB ESYLATE ↓ inhibits Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
ZOLIGRATINIB ↓ inhibits Mechanistic DGIdb
PRN1371 ↓ inhibits Mechanistic DGIdb
MUPARFOSTAT ? unclear Mechanistic DGIdb
BRIVANIB ALANINATE ↓ inhibits Mechanistic DGIdb
AST-487 ? unclear Mechanistic DGIdb
ILORASERTIB ? unclear Mechanistic DGIdb
ORANTINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 8I [PMID: 22765894] ↓ inhibits Mechanistic DGIdb
XL-999 ↓ inhibits Mechanistic DGIdb
SU-14813 ↓ inhibits Mechanistic DGIdb
RG-1530 ↓ inhibits Mechanistic DGIdb
SELUMETINIB ? unclear Mechanistic DGIdb
SU-11652 ↓ inhibits Mechanistic DGIdb
RABEPRAZOLE ↓ inhibits Mechanistic DGIdb
CP-547632 ? unclear Mechanistic DGIdb
SIROLIMUS ? unclear Mechanistic DGIdb
LENVATINIB ? unclear Mechanistic DGIdb
TYRA-200 ↓ inhibits Mechanistic DGIdb
TOZASERTIB ? unclear Mechanistic DGIdb
PEMIGATINIB ↓ inhibits Mechanistic DGIdb
GW843682X ? unclear Mechanistic DGIdb
PEGOZAFERMIN ↑ activates Mechanistic DGIdb
XL999 ? unclear Mechanistic DGIdb
BRIVANIB ↓ inhibits Mechanistic DGIdb
TINENGOTINIB ↓ inhibits Mechanistic DGIdb
SULFATINIB ↓ inhibits Mechanistic DGIdb
FUTIBATINIB ↓ inhibits Mechanistic DGIdb
TAMATINIB ? unclear Mechanistic DGIdb

Showing top 40 of 322 agents ranked by evidence tier.

IL13

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ROMILKIMAB ↓ inhibits Mechanistic DGIdb
CNTO-5825 ↓ inhibits Mechanistic DGIdb
LEBRIKIZUMAB ↓ inhibits Mechanistic DGIdb
ANRUKINZUMAB ? unclear Mechanistic DGIdb
QAX-576 ↓ inhibits Mechanistic DGIdb
TRALOKINUMAB ? unclear Mechanistic DGIdb
ADALIMUMAB ? unclear Mechanistic DGIdb
DECTREKUMAB ? unclear Mechanistic DGIdb
USTEKINUMAB ? unclear Mechanistic DGIdb
CENDAKIMAB ↓ inhibits Mechanistic DGIdb

IL22

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
EFMARODOCOKIN ALFA ? unclear Mechanistic DGIdb
FEZAKINUMAB ? unclear Mechanistic DGIdb

IL31RA

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NEMOLIZUMAB ↓ inhibits Mechanistic DGIdb

IL4

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ASPIRIN ? unclear Mechanistic DGIdb
ROMILKIMAB ↓ inhibits Mechanistic DGIdb
TEPOXALIN ? unclear Mechanistic DGIdb
PASCOLIZUMAB ? unclear Mechanistic DGIdb
CHEMBL5266734 ↓ inhibits Mechanistic 1800.0 nM (Kd) ChEMBL

IL4R

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
BIZAXOFUSP ? unclear Mechanistic DGIdb
DUPILUMAB ↓ inhibits Mechanistic DGIdb
ROMILKIMAB ? unclear Mechanistic DGIdb
MANFIDOKIMAB ? unclear Mechanistic DGIdb
PITRAKINRA ? unclear Mechanistic DGIdb
SUNITINIB ? unclear Mechanistic DGIdb
CINTREDEKIN BESUDOTOX ? unclear Mechanistic DGIdb
LIGUFALIMAB ? unclear Mechanistic DGIdb
STAPOKIBART ? unclear Mechanistic DGIdb

JAK1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TRICETAMIDE ↓ inhibits Mechanistic DGIdb
NEZULCITINIB ↓ inhibits Mechanistic DGIdb
IVARMACITINIB ↓ inhibits Mechanistic DGIdb
OCLACITINIB ↓ inhibits Mechanistic DGIdb
MOMELOTINIB ↓ inhibits Mechanistic 11.0 nM (IC50) DGIdb
DECERNOTINIB ↓ inhibits Mechanistic DGIdb
GOLIDOCITINIB ↓ inhibits Mechanistic DGIdb
UPADACITINIB ↓ inhibits Mechanistic DGIdb
LEPZACITINIB ↓ inhibits Mechanistic DGIdb
BREPOCITINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 30 [PMID: 37057760] ↓ inhibits Mechanistic DGIdb
WXFL10203614 ↓ inhibits Mechanistic DGIdb
LIRUCITINIB ↓ inhibits Mechanistic DGIdb
VEXICITINIB ↓ inhibits Mechanistic DGIdb
ILGINATINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 5E [PMID: 28580438] ↓ inhibits Mechanistic DGIdb
COMPOUND 25AP [PMID: 37796543] ↓ inhibits Mechanistic DGIdb
ZEMPROCITINIB ↓ inhibits Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
AZD1480 ↓ inhibits Mechanistic DGIdb
CERDULATINIB ↓ inhibits Mechanistic DGIdb
LONDAMOCITINIB ↓ inhibits Mechanistic DGIdb
JAK INHIBITOR 20A ↓ inhibits Mechanistic DGIdb
FILGOTINIB ↓ inhibits Mechanistic DGIdb
GUSACITINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 8L [PMID: 36053746] ↓ inhibits Mechanistic DGIdb
COMPOUND 13AC [PMID: 33256400] ↓ inhibits Mechanistic DGIdb
FEDRATINIB ↓ inhibits Mechanistic 100.0 nM (IC50) DGIdb
FILGOTINIB MALEATE ↓ inhibits Mechanistic DGIdb
PF-956980 ↓ inhibits Mechanistic DGIdb
SDC-1801 ↓ inhibits Mechanistic DGIdb
ROPSACITINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 18E [PMID: 31670517] ↓ inhibits Mechanistic DGIdb
UPADACITINIB HEMIHYDRATE ↓ inhibits Mechanistic DGIdb
BLOVACITINIB ↓ inhibits Mechanistic DGIdb
DEURUXOLITINIB ↓ inhibits Mechanistic DGIdb
RUXOLITINIB PHOSPHATE ↓ inhibits Mechanistic DGIdb
SOLCITINIB ↓ inhibits Mechanistic DGIdb
CEE321 ↓ inhibits Mechanistic DGIdb
NIK INHIBITOR 12F ↓ inhibits Mechanistic DGIdb

Showing top 40 of 233 agents ranked by evidence tier.

OSMR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
VIXARELIMAB ? unclear Mechanistic DGIdb

PDE4D

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RESVERATROL ? unclear Mechanistic DGIdb
ROLIPRAM ↓ inhibits Mechanistic 390.0 nM (IC50) DGIdb
&ALPHA;-MANGOSTIN DERIVATIVE 4E ↓ inhibits Mechanistic DGIdb
6-HYDROXY-5,7-DIMETHOXYFLAVONE ↓ inhibits Mechanistic DGIdb
TETOMILAST ↓ inhibits Mechanistic DGIdb
FLAVOXATE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DIFAMILAST ↓ inhibits Mechanistic DGIdb
CILOMILAST ↓ inhibits Mechanistic 63.0 nM (IC50) DGIdb
DOVRAMILAST ↓ inhibits Mechanistic DGIdb
CRISABOROLE ↓ inhibits Mechanistic DGIdb
VINCRISTINE ? unclear Mechanistic DGIdb
RONOMILAST ? unclear Mechanistic DGIdb
THEOPHYLLINE ↓ inhibits Mechanistic DGIdb
CDP840 ↓ inhibits Mechanistic 2.1 nM (IC50) DGIdb
LEO 29102 ↓ inhibits Mechanistic DGIdb
LIRIMILAST ? unclear Mechanistic DGIdb
QUETIAPINE FUMARATE ? unclear Mechanistic DGIdb
HT-0712 ↓ inhibits Mechanistic DGIdb
GSK-256066 ↓ inhibits Mechanistic DGIdb
COMPOUND 29 [MOSLIN ET AL., 2017] ↓ inhibits Mechanistic DGIdb
THEOPHYLLINE SODIUM GLYCINATE ↓ inhibits Mechanistic DGIdb
DYPHYLLINE ↓ inhibits Mechanistic DGIdb
MORACIN M ↓ inhibits Mechanistic DGIdb
ARCTIGENIN ↓ inhibits Mechanistic DGIdb
TOFIMILAST ? unclear Mechanistic DGIdb
PDE4 INHIBITOR 16 ↓ inhibits Mechanistic DGIdb
LOTAMILAST ↓ inhibits Mechanistic DGIdb
TRANIMILAST ↓ inhibits Mechanistic DGIdb
OGLEMILAST ? unclear Mechanistic DGIdb
CBS-3595 ↓ inhibits Mechanistic DGIdb
ENSIFENTRINE ↓ inhibits Mechanistic DGIdb
TALAROTERPHENYL A ↓ inhibits Mechanistic DGIdb
PAPAVERINE ? unclear Mechanistic DGIdb
APREMILAST ↓ inhibits Mechanistic DGIdb
TILDRAKIZUMAB ? unclear Mechanistic DGIdb
RO20-1724 ↓ inhibits Mechanistic DGIdb
MK-0359 ↓ inhibits Mechanistic DGIdb
ROFLUMILAST ↓ inhibits Mechanistic DGIdb
OXTRIPHYLLINE ↓ inhibits Mechanistic DGIdb
AWD-12-281 ? unclear Mechanistic DGIdb

Showing top 40 of 204 agents ranked by evidence tier.

TSLP

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TEZEPELUMAB ? unclear Mechanistic DGIdb
CHEMBL5593764 ↓ inhibits Mechanistic 230.0 nM (Kd) ChEMBL
CHEMBL5572561 ↓ inhibits Mechanistic 75.0 nM (Kd) ChEMBL
CHEMBL5571446 ↓ inhibits Mechanistic 29.0 nM (Kd) ChEMBL
CHEMBL5594799 ↓ inhibits Mechanistic 43.0 nM (Kd) ChEMBL
CHEMBL5574168 ↓ inhibits Mechanistic 33.0 nM (Kd) ChEMBL
CHEMBL5571168 ↓ inhibits Mechanistic 48.0 nM (Kd) ChEMBL
CHEMBL5567424 ↓ inhibits Mechanistic 290.0 nM (Kd) ChEMBL
CHEMBL5572866 ↓ inhibits Mechanistic 98.0 nM (Kd) ChEMBL
CHEMBL5595593 ↓ inhibits Mechanistic 6.0 nM (Kd) ChEMBL
CHEMBL5568693 ↓ inhibits Mechanistic 3.0 nM (Kd) ChEMBL
CHEMBL5589702 ↓ inhibits Mechanistic 33.0 nM (Kd) ChEMBL
CHEMBL5542413 ↓ inhibits Mechanistic 14.0 nM (Kd) ChEMBL
CHEMBL5574722 ↓ inhibits Mechanistic 6.0 nM (Kd) ChEMBL
CHEMBL5583600 ↓ inhibits Mechanistic 9.0 nM (Kd) ChEMBL
CHEMBL5593210 ↓ inhibits Mechanistic 13.0 nM (Kd) ChEMBL
CHEMBL5574606 ↓ inhibits Mechanistic 20.0 nM (Kd) ChEMBL
CHEMBL5573129 ↓ inhibits Mechanistic 36.0 nM (Kd) ChEMBL
CHEMBL5563474 ↓ inhibits Mechanistic 3.0 nM (Kd) ChEMBL
CHEMBL5569104 ↓ inhibits Mechanistic 6.0 nM (Kd) ChEMBL
CHEMBL5573652 ↓ inhibits Mechanistic 3.0 nM (Kd) ChEMBL
CHEMBL5594472 ↓ inhibits Mechanistic 2.0 nM (Kd) ChEMBL
CHEMBL5571424 ↓ inhibits Mechanistic 13.0 nM (Kd) ChEMBL
CHEMBL5564963 ↓ inhibits Mechanistic 900.0 nM (Kd) ChEMBL
CHEMBL5564182 ↓ inhibits Mechanistic 52.0 nM (Kd) ChEMBL
CHEMBL5571015 ↓ inhibits Mechanistic 97.0 nM (Kd) ChEMBL
CHEMBL5572417 ↓ inhibits Mechanistic 77.0 nM (Kd) ChEMBL
CHEMBL5567113 ↓ inhibits Mechanistic 664.0 nM (Kd) ChEMBL
CHEMBL5573827 ↓ inhibits Mechanistic 82.0 nM (Kd) ChEMBL
CHEMBL5572731 ↓ inhibits Mechanistic 1500.0 nM (Kd) ChEMBL
CHEMBL5589795 ↓ inhibits Mechanistic 31.0 nM (Kd) ChEMBL
CHEMBL5570697 ↓ inhibits Mechanistic 100.0 nM (Kd) ChEMBL
CHEMBL5569889 ↓ inhibits Mechanistic 70.0 nM (Kd) ChEMBL
CHEMBL5563347 ↓ inhibits Mechanistic 110.0 nM (Kd) ChEMBL
CHEMBL5563312 ↓ inhibits Mechanistic 130.0 nM (Kd) ChEMBL
CHEMBL5579715 ↓ inhibits Mechanistic 200.0 nM (Kd) ChEMBL
CHEMBL5572108 ↓ inhibits Mechanistic 6.0 nM (Kd) ChEMBL
CHEMBL5570404 ↓ inhibits Mechanistic 260.0 nM (Kd) ChEMBL
CHEMBL5567065 ↓ inhibits Mechanistic 130.0 nM (Kd) ChEMBL
CHEMBL5564500 ↓ inhibits Mechanistic 14.0 nM (Kd) ChEMBL

Showing top 40 of 51 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Atopic Dermatitis (Eczema): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

PRA-216 Atopic Dermatitis Safety and Efficacy Study Recruiting
NCT07810777 Phase: 2 Started: 2026-09-17

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)

Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis Recruiting
NCT06934252 Phase: 1 Started: 2025-05-02

This Phase 1a/1b randomized, double-blind, placebo-controlled study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with moderate-to-severe atopic dermatitis (AD). The number of dosing cohorts may be in...

A Study Evaluating TRIV-573 in Atopic Dermatitis Recruiting
NCT07782333 Phase: 2 Started: 2026-09-09

The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duration...

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis Active Not Recruiting
NCT07223697 Phase: 2 Started: 2026-01-08

This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis Recruiting
NCT07895615 Phase: 2 Started: 2026-10

The goal of this clinical trial is to learn if drug LT-002-158 works to treat moderate-to-severe atopic dermatitis in adults. It will also learn about the safety of drug LT-002-158. The main questions it aims to answer are: Does drug LT-002-158 reduce the signs and symptoms of moderate-to-severe ato...

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 Recruiting
NCT07453602 Phase: 1 Started: 2026-03-02

This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants wit...

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants Completed
NCT06268860 Phase: 1 Started: 2024-02-15

The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis Active Not Recruiting
NCT05995964 Phase: 2 Started: 2023-08-22

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. *...

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis Recruiting
NCT07003425 Phase: 2 Started: 2025-05-14

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will c...

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema Recruiting
NCT07783425 Phase: 3 Started: 2026-08-24

The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin. The study is seeking partici...

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy Completed
NCT05958407 Phase: 3 Started: 2023-08-28

The purpose of this study is to test if treatment with tralokinumab is safe and efficacious in treating moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and ...

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis Recruiting
NCT07690371 Phase: 3 Started: 2026-06-29

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximat...

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Completed
NCT03989206 Phase: 3 Started: 2019-12-30

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis Recruiting
NCT07762833 Phase: 3 Started: 2026-10-08

This is a bridging study only for Chinese subjects. The goal of this clinical trial is to learn if drug Nemolizumab works to treat moderate to severe AD in over 12 years old male and female. It will also learn about the safety of drug Nemolizumab. Researchers will compare drug Nemolizumab to a place...

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis Completed
NCT06280716 Phase: 3 Started: 2024-04-24

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.

Agents Found By Disease-Level Search

Searched directly from “Atopic Dermatitis (Eczema)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 11-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

52 agents shown (approved or with trial evidence) — 46 not found by the gene-target search above.

Nemolizumab

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT05405985 NCT05405985 NCT03989349

Dupilumab

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT06415175 NCT02395133 NCT02647086

tacrolimus ointmentNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT00480896 NCT00654355 NCT05607901

Tralokinumab

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT05938478 NCT04587453 NCT03761537

betamethasone valerateNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00576238 NCT00576238

stapokibart (CM310)NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT04805411 NCT04893707

Modified Qing-Ying DecoctionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04419584

emollient (Cetaphil cream)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00806221

LNK01004 ointment 0.3%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06553287

LNK01004 ointment 1.0%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06553287

LNK01004 ointment 1.5%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06553287

Period 1 - Day 1: PF-04965842 administeredNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03634345

Period 2: Cohort 1: Fluvoxamine & PF-04965842NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03634345

Period 2: Cohort 2: Fluconazole & PF-04965842NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03634345

The novel electrolyzed water sprayNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05770271

difamilast (OPA-15406)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01702181

TacrolimusNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01702181

Intact Cow's Milk Protein FormulaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04763512

Partially Hydrolysed Whey FormulaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04763512

Locoid LipocreamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02153762

Hylatopic PlusNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02153762

1% OPA-15406 OintmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05667623

ifidancitinib (ATI-502)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03585296

Ruxolitinib Topical Cream 1.5%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06673654

OPZELURA (Ruxolitinib) CreamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06673654

Difamilast

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05571943

zabalafinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06855745

GM-XANTHO onitmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04369846

Hydrocortisone 1% creamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05607901

Ustekinumab

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01945086

tapinarof (WBI-1001)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT00837551

VC005NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07329101

Tri-lipid skin barrier cream (Epiceram)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03742414

Fluticasone propionate Cream 0.05%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03742414

MapracoratNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01359787

taurodeoxycholic acid (HY209)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03492398

PimecrolimusNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00120302

EpiCeram Skin Barrier EmulsionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02691507

Experimental Product 1% Colloidal Oatmeal BalmNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02691507

BarzolvolimabNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06727552

Epaderm CreamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03738163

LEO 39652 creamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02219633

BGB-45035NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06342713

CBP-201NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04444752

AlefaceptNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00832585

Tacrolimus Ointment 0.1%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00534508

BMX-010NOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03381625

Roflumilast Cream 0.15%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04773587

TRIV-509NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07167758

Placebo for UpadacitinibNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03569293

Upadacitinib

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03569293

611NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06173284

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.